Targeting SHP2 as a promising strategy for cancer immunotherapy
Several studies have shown that SHP2 plays an important role in regulating immune cell functions in tumor microenvironment. A few clinical trials conducted using SHP2 allosteric inhibitors …
Strategies to overcome drug resistance using SHP2 inhibitors
Encoded by PTPN11, the SHP2 (Src homology-2 domain-containing protein tyrosine phosphatase-2) is widely recognized as a carcinogenic phosphatase. As a promising anti …
Targeting SHP1 and SHP2 to suppress tumors and enhance
Nov 21, 2024 · Given their expression and crucial roles in both tumor and immune cells, SHP1 and SHP2 represent promising drug targets for antitumor therapeutic interventions. Recent …
A comprehensive review of SHP2 and its role in cancer
In view of this, we comprehensively and thoroughly reviewed literatures about SHP2 regulatory mechanisms, substrates and binding partners, biological functions, roles in human cancers, …
SHP-2 and PD-1-SHP-2 signaling regulate myeloid cell ... - Nature
Dec 29, 2022 · SHP-2 and the PD-1-SHP-2 signaling restrained the GM-CSF-mediated phosphorylation of HOXA10 and IRF8, which induce myeloid differentiation and monocyte/DC …
Targeting SHP2 for Cancer Treatment: Advances and Prospects
Jan 4, 2023 · In this chapter, we comprehensively summarize the multifaceted functions of SHP2 and the structural basis of SHP2 under different conditions. Additionally, the challenges and …
Overcoming Immune Checkpoint Therapy Resistance with SHP2 …
As SHP2 is at the crossroads of many functions and pathways, this molecule can be leveraged for therapeutic targeting in cancer. SHP2 inhibitors have shown promise in overcoming resistance …
Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current ...
Oct 22, 2020 · Recent discovery of allosteric inhibitors has inspired a novel approach to selectively target SHP2 via the noncatalytic site. To date, four SHP2 allosteric inhibitors have …
SHP-2 in Lymphocytes' Cytokine and Inhibitory Receptor Signaling
Oct 25, 2019 · SHP-2 possesses two N-terminal SH2 domains (N-SH2 and C-SH2) and a central protein tyrosine phosphatase (PTP) core (Figure 1) (3, 4, 27 – 30). The PTP domain is highly …
SHP2: A Pleiotropic Target at the Interface of Cancer and Its ...
Nov 1, 2023 · SHP2 modulates the signaling downstream of oncogenic RTKs and is found hyperactivated in gastric carcinoma (4), anaplastic large cell lymphoma (5), glioblastoma (6), …